PDCD1 and non-small cell lung carcinoma: Our findings, albeit preliminary, suggest that CTC characterization according to IDO and PD-L1 may promote our understanding of the mechanisms underlying immunotherapy resistance and may provide valuable prognostic information for NSCLC patients treated with anti-PD1 ICIs.